---
title: "Yubo International Biotech Limited | 10-K: FY2025 Revenue: USD 12.35 K"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281237262.md"
datetime: "2026-03-31T20:14:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281237262.md)
  - [en](https://longbridge.com/en/news/281237262.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281237262.md)
generator: "portal-rs"
---

# Yubo International Biotech Limited | 10-K: FY2025 Revenue: USD 12.35 K

Revenue: As of FY2025, the actual value is USD 12.35 K.

EPS: As of FY2025, the actual value is USD -0.01.

EBIT: As of FY2025, the actual value is USD -1.187 M.

#### Sales

Sales for Yubo International Biotech Limited increased by $8,883, or 256%, to $12,353 for the year ended December 31, 2025, compared to $3,470 for the year ended December 31, 2024, despite the total sales volume remaining immaterial. 

#### Cost of Goods Sold

The cost of goods sold rose by $3,366, or 409%, to $4,188 in 2025, from $822 in 2024, in line with the increase in sales. 

#### Gross Profit

Gross profit increased by $5,517, or 208%, reaching $8,165 in 2025, up from $2,648 in 2024, primarily due to the increase in sales. 

#### Operating Expenses

Operating expenses decreased by $576,706, or 33%, to $1,195,861 in 2025, from $1,772,567 in 2024, mainly due to decreases in office lease occupancy expense and other operating expenses, specifically the early termination of a lease for Yubo Shenzhen. 

#### Loss from Operations

Loss from operations decreased by $582,223, or 33%, to -$1,187,696 in 2025, compared to -$1,769,919 in 2024, driven primarily by the decrease in operating expenses. 

#### Other Expenses

Other expenses decreased by $211,630, or 100%, to -$243 in 2025, from -$211,873 in 2024, mainly due to a loss on obsolete inventory in the third quarter of 2024 that did not recur in fiscal year 2025. 

#### Net Loss

Net loss decreased by $793,853, or 40%, to -$1,187,939 in 2025, compared to -$1,981,792 in 2024, primarily due to the decrease in operating expenses. 

#### Cash Flow

Net cash used in operating activities decreased by $494,927, or 37%, to -$842,802 in 2025, from -$1,337,729 in 2024, primarily due to a reduction in net loss. Net cash provided by investing activities was $0 in 2025, a decrease of $118,431 or 100% from $118,431 in 2024, mainly due to a decrease in equipment sales. Net cash provided by financing activities decreased by $557,594, or 40%, to $849,545 in 2025, from $1,407,139 in 2024, primarily due to less financial support from related parties. 

#### Liquidity and Capital Resources

As of December 31, 2025, Yubo International Biotech Limited had cash and cash equivalents of $8,062 and negative working capital of -$2,123,785. Short-term borrowings from directors totaled $1,211,440 as of December 31, 2025. Shareholder loans amounting to $2,530,000 were settled on July 23, 2025. 

#### Contractual Obligations

As of December 31, 2025, principal commitments for operating lease obligations totaled $79,742, all due within less than one year. 

#### Outlook/Guidance

Management believes existing cash, working capital, and continuous financial support from the largest shareholder will be sufficient to meet anticipated cash requirements through 2026. The company plans to seek additional capital in 2026, though there is no assurance of success, and future financing may dilute existing stockholders. The company’s history of losses and negative working capital raises substantial doubt about its ability to continue as a going concern.

### Related Stocks

- [YBGJ.US](https://longbridge.com/en/quote/YBGJ.US.md)

## Related News & Research

- [Ocean Power says Form 10-K contains going concern qualification](https://longbridge.com/en/news/296666212.md)
- [NAPC Defense announces availability of fiscal 2026 Form 10-K report](https://longbridge.com/en/news/296821941.md)
- [CXJ Group flags late filing of annual report for year ended May 31, 2026](https://longbridge.com/en/news/297305685.md)
- [iBio FY 2026: Revenue $100K, Net income ($33.04M), EPS ($0.32) — 10-K Summary](https://longbridge.com/en/news/297327928.md)
- [AiRWA gets Nasdaq deficiency notice over late 2026 Form 10-K filing](https://longbridge.com/en/news/297369709.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**